Table 2.
Univariable analyses (Cox proportional hazards model) of patient and clinical characteristics and their associations with PFS and OS in the whole cohort.
| Variable | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| n | HR | 95% CI | p | n | HR | 95% CI | p | |
| Age (years) | ||||||||
| <50 | 46 | 1 (ref) | 46 | 1 (ref) | ||||
| 50–60 | 166 | 1.07 | 0.71–1.60) | 0.762 | 169 | 1.49 | (0.90–2.45) | 0.118 |
| >60 | 902 | 1.04 | (0.72–1.51) | 0.818 | 902 | 1.68 | (1.06–2.67) | 0.027 |
| Sex | ||||||||
| Women | 590 | 1 (ref) | 592 | 1 (ref) | ||||
| Men | 524 | 1.10 | (0.94–1.27) | 0.233 | 525 | 1.13 | (0.96–1.34) | 0.137 |
| Smoking history | ||||||||
| Never | 126 | 1 (ref) | 126 | 1 (ref) | ||||
| Former/current | 988 | 1.48 | (1.15–1.91) | 0.002 | 991 | 1.59 | (1.19–2.12) | 0.002 |
| ECOG PS | ||||||||
| 0–1 | 1034 | 1 (ref) | 1037 | 1 (ref) | ||||
| 2 | 59 | 4.30 | (3.24–5.71) | <0.001 | 59 | 6.41 | (4.80–8.56) | <0.001 |
| 3–4 | 21 | 4.55 | (2.76–7.48) | <0.001 | 21 | 6.91 | (4.18–11.41) | <0.001 |
| Stage | ||||||||
| I | 359 | 1 (ref) | 359 | 1 (ref) | ||||
| II | 148 | 2.15 | (1.61–2.86) | <0.001 | 148 | 2.11 | (1.51–2.95) | <0.001 |
| III | 230 | 4.37 | (3.43–5.57) | <0.001 | 230 | 3.89 | (2.93–5.15) | <0.001 |
| IV | 377 | 12.74 | (10.01–16.09) | <0.001 | 380 | 12.46 | (9.61–16.14) | <0.001 |
| Surgery | ||||||||
| No | 534 | 1 (ref) | 534 | 1 (ref) | ||||
| Yes | 580 | 0.15 | (0.12–0.17) | <0.001 | 583 | 0.13 | (0.11–0.16) | <0.001 |
| Curative RT +/− CT first line | ||||||||
| No | 1023 | 1 (ref) | 1023 | 1 (ref) | ||||
| Yes | 91 | 1.28 | (0.99–1.64) | 0.060 | 91 | 1.05 | (0.78–1.43) | 0.740 |
| Palliative CT and/or RT first line | ||||||||
| No | 843 | 1 (ref) | 846 | 1 (ref) | ||||
| Yes | 271 | 5.75 | (4.85–6.81) | <0.001 | 271 | 5.54 | ((4.64–6.63)) | <0.001 |
| History of TKI (any line) | ||||||||
| No | 1025 | 1 (ref) | 1028 | 1 (ref) | ||||
| Yes | 89 | 1.56 | (1.22–1.99) | <0.001 | 89 | 1.32 | (0.86–2.03) | 0.198 |
| History of ICI (any line) | ||||||||
| No | 939 | 1 (ref) | 941 | 1 (ref) | ||||
| Yes | 175 | 2.19 | (1.81–2.64) | <0.001 | 176 | 1.39 | ((1.11–1.74)) | 0.006 |
| KRAS status | ||||||||
| Wild type | 695 | (1 (ref) | 697 | 1 (ref) | ||||
| Mutated | 419 | 1.04 | (0.89–1.21) | 0.664 | 420 | 1.01 | (0.85–1.19) | 0.940 |
| KRAS G12C status | ||||||||
| Wild type | 695 | 1 (ref) | 697 | 1 (ref) | ||||
| G12C | 192 | 0.91 | (0.74–1.12) | 0.379 | 193 | 0.91 | (0.72–1.14) | 0.414 |
| KRAS non-G12C | 227 | 1.15 | (0.96–1.39) | 0.132 | 227 | 1.10 | (0.89–1.35) | 0.383 |
| Raf vs. PI3K preference | ||||||||
| Raf | 245 | 1 (ref) | 245 | 1 (ref) | ||||
| PI3K | 69 | 1.11 | (0.79–1.55) | 0.554 | 70 | 1.09 | (0.75–1.58) | 0.649 |
| Ral A/B vs. PI3K preference | ||||||||
| RalA/B | 192 | 1 (ref) | 192 | 1 (ref) | ||||
| PI3K | 69 | 1.20 | (0.85–1.70) | 0.312 | 70 | 1.19 | (0.81–1.74) | 0.385 |
| Type KRAS mutation | ||||||||
| G12A | 30 | 1 (ref) | 30 | 1 (ref) | ||||
| G12C | 192 | 0.62 | (0.38–1.00) | 0.050 | 192 | 0.59 | (0.35–0.99) | 0.044 |
| G12V | 81 | 0.72 | (0.43–1.21) | 0.220 | 81 | 0.60 | (0.34–1.06) | 0.080 |
| G12D | 69 | 0.74 | (0.44–1.26) | 0.274 | 70 | 0.69 | (0.39–1.24) | 0.216 |
Abbreviations: PFS, progression free survival; OS, overall survival; HR, hazard ratio; ref reference; ECOG PS, Eastern Cooperative Oncology Group performance status; CT, chemotherapy; RT, radiotherapy; TKI, tyrosine kinase inhibitor; ICI, immune checkpoint inhibitor.